Two GLP-1 medicines are FDA-approved for weight management in teenagers 12 and older with obesity: Wegovy (semaglutide 2.4 mg) and Saxenda (liraglutide), according to their labels read November 20, 2026. Zepbound is approved only for adults, and compounded GLP-1s are not FDA-approved for anyone. Of the programs we score, only Mochi Health describes a teen program.
Takeaway: a teen can be prescribed a GLP-1 through telehealth, but only some medicines carry a pediatric approval and very few programs say they treat minors. A parent should be part of every visit.
Parents ask us two questions about GLP-1 drugs and teenagers: is it allowed, and can it be done online? The answers depend on which medicine, which program and which teen. This guide sets out what the FDA labels say, what the adolescent trials found, what the telehealth programs we review publish about minors, and a checklist to take into the first visit. It is not medical advice, and a GLP-1 decision for a child belongs with a clinician who knows the child.
Which GLP-1 medicines are approved for teenagers?
Two are. Wegovy’s label covers “adults and pediatric patients aged 12 years and older with obesity”, and Saxenda’s covers patients 12 and older “with body weight greater than 60 kg and obesity.” Both are injections. Zepbound’s label covers adults only, for weight management and for moderate to severe sleep apnea, so prescribing it to a teen would be off-label. The once-daily Wegovy pill is an adult product; its safety information says it is not known whether the tablets are safe and effective under 18.
Compounded semaglutide and tirzepatide are a different category. FDA does not approve compounded drugs, and no adolescent trial has tested them. Everything below about results and side effects comes from trials of the brand-name products.
| Medicine | Ages approved for weight management | Label conditions for teens | Dosing | Label source |
|---|---|---|---|---|
| Wegovy (semaglutide 2.4 mg) injection | Adults and patients 12 and older | Ages 12+ “with obesity” | Once weekly | Wegovy label (openFDA version effective April 23, 2024) |
| Saxenda (liraglutide 3.0 mg) injection | Adults and patients 12 and older | Ages 12+ with body weight above 60 kg and obesity | Once daily | Saxenda label (effective February 25, 2026) |
| Zepbound (tirzepatide) injection | Adults only | Not approved under 18 | Once weekly | Zepbound label (effective August 28, 2026) |
| Wegovy pill (oral semaglutide) | Adults | Its safety information says it is not known whether the tablets are safe and effective under 18 | Once daily | Manufacturer safety information as reproduced on lifemd.com, read November 20, 2026 |
| Compounded semaglutide or tirzepatide | Not FDA-approved for anyone | No pediatric trial data | Varies | FDA consumer page, current as of October 1, 2026 |
What did the adolescent trials show?
Three large trials have tested GLP-1 drugs in 12- to 17-year-olds. Their results are reported in body-mass index (BMI) terms because teens are still growing, which makes weight alone a moving target.
STEP TEENS (semaglutide). 201 adolescents with obesity were randomly assigned, two to one, to weekly semaglutide 2.4 mg or placebo for 68 weeks, both with lifestyle counseling. Average BMI fell 16.1% with semaglutide and rose 0.6% with placebo. Of the teens on semaglutide, 73% lost at least 5% of their body weight, compared with 18% on placebo. Ninety percent completed treatment.
The liraglutide trial. 251 adolescents who had not responded to lifestyle therapy alone took daily liraglutide 3.0 mg or placebo for 56 weeks. BMI fell 4.64 percentage points more with liraglutide, and 43.3% reached at least a 5% BMI reduction, against 18.7% on placebo. The trial then stopped the drug for 26 weeks, and the BMI standard-deviation score rose more in the liraglutide group than in the placebo group after it was stopped.
SURMOUNT-ADOLESCENTS (tirzepatide). Lilly’s November 14, 2026 release, issued for the ObesityWeek meeting, says Zepbound reduced BMI by an average 21.4% at 72 weeks in adolescents, and that more than half no longer met the BMI criteria for obesity. This is a company summary of conference data, not a peer-reviewed paper, and Lilly’s own release still describes Zepbound as indicated for adults.
| Trial | Drug and dose | Length | Main result | Status of the evidence |
|---|---|---|---|---|
| STEP TEENS (201 teens) | Semaglutide 2.4 mg weekly vs placebo | 68 weeks | BMI −16.1% vs +0.6%; 73% vs 18% lost at least 5% of body weight | Peer-reviewed, NEJM 2022 |
| Liraglutide adolescent trial (251 teens) | Liraglutide 3.0 mg daily vs placebo | 56 weeks, then 26 weeks off drug | BMI cut 4.64 percentage points more than placebo; at least 5% BMI reduction in 43.3% vs 18.7% | Peer-reviewed, NEJM 2020 |
| SURMOUNT-ADOLESCENTS | Tirzepatide (Zepbound) | 72 weeks | BMI reduced by an average 21.4%; more than half no longer met the BMI criteria for obesity | Company release, November 14, 2026; Zepbound still approved only for adults |
Put simply, using the STEP TEENS numbers: in a group of 100 teens like those in the trial, about 73 on semaglutide and about 18 on placebo would lose at least 5% of their weight over 68 weeks. That is 55 more teens per 100 reaching the threshold, and it still leaves about 27 of 100 on the drug who did not.
What side effects and warnings should parents know about?
Stomach side effects were the most common problem in both published trials. In STEP TEENS they affected 62% of teens on semaglutide and 42% on placebo; five participants on semaglutide (4%) developed gallstones, and serious adverse events were reported in 11% versus 9%. In the liraglutide trial, gastrointestinal events affected 64.8% versus 36.5%, and 10.4% of teens on liraglutide stopped treatment because of adverse events, against none on placebo.
The Wegovy label lists warnings that apply to every patient, including a boxed warning about thyroid C-cell tumors seen in rodents, acute pancreatitis, gallbladder disease, kidney injury, and suicidal behavior and ideation, which the label asks prescribers to monitor. On November 9, 2026, FDA added another: it is requiring every approved GLP-1 medicine to warn about a possible increased risk of NAION, a sudden, painless loss of vision in one eye. In FDA’s analysis of 126 trials the rate was 6.4 versus 3.8 cases per 100,000 person-years, a small absolute difference. Any sudden vision change is a reason to call a clinician the same day.
Two trial findings matter for planning. First, side effects are most common while the dose is being raised. Second, the liraglutide trial showed the BMI standard-deviation score climbing again after the drug stopped, so a family should discuss up front whether treatment is expected to be long term and what happens if it ends.
Can a teenager get a GLP-1 through a telehealth program?
Some programs allow it; most say nothing. We read the pages of the ten GLP-1 programs we scored on November 20, 2026. Mochi Health’s FAQ describes a pediatrics program for teens 13 to 17: “A parent or guardian creates the account, joins the video visit with a provider who sees teens, and helps decide on medication.” Form Health’s FAQ says patients must be 18 or older. The pages we read for the other eight programs did not state an age policy, so ask before you sign up.
A few practical points follow from the labels. A program that offers only compounded drugs cannot offer an FDA-approved pediatric treatment, because no compounded GLP-1 is approved. A program that prescribes brand drugs through insurance can, but insurance rules for teens vary by plan. On cost, NovoCare’s self-pay page, read November 20, 2026, lists the Wegovy pen at $349 a month (with $199 for each of the first two fills for new patients through December 31, 2026). That is $4,188 for twelve months at full price, or $3,888 with the two introductory fills ($398 plus 10 fills at $349). The page does not say whether self-pay applies to patients under 18, so confirm with the pharmacy.
A checklist for parents before the first visit
- Which medicine, and is it approved for this age? Ask for the drug name and confirm the label covers 12 and older. Wegovy and Saxenda do; Zepbound and the Wegovy pill are adult products.
- Who is the prescriber? Ask whether the clinician treats adolescents and look them up in the NPPES NPI Registry. Our provider-checking guide shows how.
- Will a parent join every visit? Mochi’s model requires a parent or guardian at the video visit. Expect the same from any program.
- How will growth, nutrition and mood be monitored? Ask how often visits happen, who reviews side effects, and how the program screens for eating disorders.
- What is the plan if treatment stops? The liraglutide trial showed regain after stopping. Ask what follow-up looks like.
- What will it cost for a year? Add program fees, the medicine and any lab work, and multiply by 12.
What this means for you
For a teen with obesity, the evidence supports two approved GLP-1 options, Wegovy and Saxenda, with meaningful but uneven results and common stomach side effects. A tirzepatide option for teens has encouraging company-reported data but no pediatric approval. Telehealth can be a route in, but only a few programs say they treat minors, and the visit should include a parent and a clinician experienced with adolescents. Start with your child’s pediatrician, who can coordinate with any program. Our clinical page on GLP-1s in adolescents covers the pharmacology, the Mochi Health review explains that program’s scores and prices, and our side-effects reference and compounded vs brand guide fill in the rest.
Frequently asked questions
Is Wegovy approved for teenagers?
Yes. Wegovy’s FDA label, read November 20, 2026, covers adults and pediatric patients aged 12 years and older with obesity, alongside a reduced-calorie diet and more physical activity. In the STEP TEENS trial, teens on Wegovy’s 2.4 mg dose cut their BMI by an average 16.1% over 68 weeks, compared with a 0.6% rise on placebo.
Is Zepbound approved for people under 18?
No. Zepbound’s label, effective August 28, 2026, covers adults only. Lilly announced on November 14, 2026 that tirzepatide reduced BMI by an average 21.4% at 72 weeks in the SURMOUNT-ADOLESCENTS trial, but that is company-reported conference data, and Lilly’s release still describes Zepbound as indicated for adults.
Can a teenager get compounded semaglutide online?
Compounded semaglutide is not FDA-approved for anyone, and no trial has tested it in adolescents. The teen results in this guide come from the brand-name drugs. If a program offers only compounded products, it cannot offer an FDA-approved pediatric treatment. Ask your child’s pediatrician about the approved options first.
Which telehealth programs treat teenagers?
Of the ten GLP-1 programs we scored on November 20, 2026, only Mochi Health’s FAQ describes a pediatrics program, for ages 13 to 17, with a parent or guardian on the video visit. Form Health’s FAQ says patients must be 18 or older. The other programs’ pages we read did not state an age policy.
What are the most common side effects in teens?
Stomach problems. In STEP TEENS, gastrointestinal side effects affected 62% of teens on semaglutide versus 42% on placebo, and 4% on semaglutide developed gallstones. In the liraglutide trial, 64.8% had gastrointestinal events versus 36.5%, and 10.4% stopped treatment because of side effects. The labels also warn about pancreatitis and suicidal thoughts.
What happens if a teen stops taking a GLP-1?
In the liraglutide adolescent trial, which stopped the drug for 26 weeks after 56 weeks of treatment, the BMI standard-deviation score rose more in the group that had taken liraglutide than in the placebo group. Families should discuss with the prescriber, before starting, whether treatment is expected to be long term and how follow-up will work if it ends.
Sources
- Wegovy (semaglutide) injection prescribing information, via openFDA and DailyMed (label version effective April 23, 2024); read November 20, 2026.
- Saxenda (liraglutide) injection prescribing information, label effective February 25, 2026; read November 20, 2026.
- Zepbound (tirzepatide) prescribing information, label effective August 28, 2026; read November 20, 2026.
- Weghuber D, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). N Engl J Med. 2022;387:2245-2257; abstract read November 20, 2026.
- Kelly AS, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382:2117-2128; abstract read November 20, 2026.
- Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, Eli Lilly release, November 14, 2026; read November 20, 2026 (portfolio news research).
- FDA requires safety labeling changes for GLP-1 receptor agonists due to potential risk of NAION, FDA Drug Safety Communication, November 9, 2026; read November 20, 2026.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of October 1, 2026; read November 20, 2026.
- Hampl SE, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023;151(2):e2022060640; citation read November 20, 2026.
- Mochi Health FAQ (pediatrics program) and Form Health FAQ (age requirement), read November 20, 2026.
- NovoCare Wegovy self-pay pricing, read November 20, 2026.